Odyssey Therapeutics, Inc. ODTX
20.00 USD +0.85 (+4.44%)
At closeNov 10, 2026, 4:41 PM EST
20.00 0.00 0.00%
After hours · Nov 10, 4:41 PM ET
18.71 Day range 20.86
15.10 52-week range 29.05
- YTD
- +21.80%
- 1 year
- +21.80%
News
benzinga.com Odyssey Therapeutics Publishes Paper Titled 'TNFR2 agonism increases tissue and effector Treg cells In Journal Of Immunology Odyssey Therapeutics, Inc. (Nasdaq: ODTX) ("Odyssey" or the "Company"), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and
benzinga.com HC Wainwright & Co. Assumes Odyssey Therapeutics at Buy, Announces Price Target of $40 HC Wainwright & Co. analyst Joseph Pantginis assumes Odyssey Therapeutics (NASDAQ:ODTX) with a Buy rating and announces Price Target of $40.
benzinga.com Odyssey Therapeutics Q3 EPS $(1.10) Misses $(1.08) Estimate Odyssey Therapeutics (NASDAQ:ODTX) reported quarterly losses of $(1.10) per share which missed the analyst consensus estimate of $(1.08) by 1.85 percent.
globenewswire.com Odyssey Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update Additional analyses from the Phase 2a induction period for OD-001 further strengthen clinical proof of concept in ulcerative colitis Completed IND-enabling studies for OD-002, a first-in-class oral…
marketbeat.com Odyssey Therapeutics Highlights OD-001 Phase IIa UC Data, Sets 2027 Trial Readouts Odyssey Therapeutics NASDAQ: ODTX presented additional data from its open-label Phase IIa trial of OD-001, an oral RIPK2 scaffolding inhibitor for moderate-to-severe ulcerative colitis, during its…
seekingalpha.com Odyssey Therapeutics, Inc. (ODTX) Discusses Additional Phase IIa Data for OD-001 in Ulcerative Colitis from UEG Week Presentation Transcript Odyssey Therapeutics, Inc. (ODTX) Discusses Additional Phase IIa Data for OD-001 in Ulcerative Colitis from UEG Week Presentation Transcript
globenewswire.com Odyssey Therapeutics Presents Completed Phase 2a OD-001 Induction Results Strengthening Clinical Proof of Concept at UEG Week 2026 Favorable tolerability profile and oral administration underscore the potential of OD-001 as a monotherapy and backbone for combination regimens in IBD
benzinga.com UBS Initiates Coverage On Odyssey Therapeutics with Buy Rating, Announces Price Target of $27 UBS analyst Alice Nettleton initiates coverage on Odyssey Therapeutics (NASDAQ:ODTX) with a Buy rating and announces Price Target of $27.
247wallst.com Here Are Monday’s Top Wall Street Analyst Research Calls: Adobe, Biogen, First Solar, GoDaddy, Hubspot, Palantir Technologies, Robinhood Markets, Snowflake, TeraWulf, T-Mobile US and More Big banks kick off third-quarter earnings season tomorrow, and Wall Street analysts are already reshuffling their bets with a wave of surprise upgrades, downgrades, and fresh initiations across some…
benzinga.com Odyssey Therapeutics To Present Design Of Randomized, Double-Blind Phase 2a Trial Evaluating OD-001 In Combination With Vedolizumab In Patients With UC At ACG 2026 Annual Scientific Meeting Odyssey Therapeutics, Inc. (NASDAQ:ODTX) ("Odyssey" or the "Company"), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and- benzinga.com Raymond James Initiates Coverage On Odyssey Therapeutics with Outperform Rating, Announces Price Target of $42 Raymond James analyst Thomas Deal initiates coverage on Odyssey Therapeutics (NASDAQ:ODTX) with a Outperform rating and announces Price Target of $42.
globenewswire.com Odyssey Therapeutics Announces Oral Presentation of Additional Phase 2a Induction Data for OD-001 in Ulcerative Colitis at UEG Week 2026 Company to host conference call and webcast following the presentation on Tuesday, October 20, at 8:00 a.m. EDT BOSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX)…
defenseworld.net Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Stock Has Consensus Target Price of $35.75 According to Brokerages Shares of Odyssey Therapeutics, Inc. (NASDAQ: ODTX - Get Free Report) have earned an average rating of "Moderate Buy" from the eight research firms that are covering the company, MarketBeat Ratings…
seekingalpha.com Odyssey Therapeutics, Inc. (ODTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Odyssey Therapeutics, Inc. (ODTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
globenewswire.com Odyssey Therapeutics to Participate in Stifel 2026 Virtual Immunology and Inflammation Forum BOSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care…
benzinga.com This Ascendis Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday Analysts initiate coverage and change ratings on top stocks like ASND, DOCN, ODTX, MT, and NVCT. See their price targets and views on these stocks.
benzinga.com HC Wainwright & Co. Initiates Coverage On Odyssey Therapeutics with Buy Rating, Announces Price Target of $44 HC Wainwright & Co. analyst Emily Bodnar initiates coverage on Odyssey Therapeutics (NASDAQ:ODTX) with a Buy rating and announces Price Target of $44.
globenewswire.com Odyssey Therapeutics to Participate in Upcoming Investor Conferences BOSTON, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care…
benzinga.com JP Morgan Maintains Overweight on Odyssey Therapeutics, Raises Price Target to $29 JP Morgan analyst Brian Cheng maintains Odyssey Therapeutics (NASDAQ:ODTX) with a Overweight and raises the price target from $26 to $29.
gurufocus.com Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases PR Newswire
benzinga.com Odyssey Taps Evotec's AI-Driven Discovery Platform To Advance Autoimmune, Inflammatory Disease Programs Collaboration combines Odyssey's disease biology expertise with Evotec's AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries to support advancement of…
prnewswire.com Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases Collaboration combines Odyssey's disease biology expertise with Evotec's AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries to support advancement of…
globenewswire.com Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Data from the Phase 2a monotherapy trial of OD-001 accepted for oral presentation at United European Gastroenterology Week in October Phase 2a combination trial of OD-001 with vedolizumab and Phase…- benzinga.com Oppenheimer Reiterates Outperform on Odyssey Therapeutics, Maintains $40 Price Target Oppenheimer analyst Jeff Jones reiterates Odyssey Therapeutics (NASDAQ:ODTX) with a Outperform and maintains $40 price target.
- benzinga.com Odyssey Therapeutics Q1 EPS $(6.77) Misses $(1.13) Estimate Odyssey Therapeutics (NASDAQ:ODTX) reported quarterly losses of $(6.77) per share which missed the analyst consensus estimate of $(1.13) by 499.12 percent. This is a 82.8 percent increase over losses…
globenewswire.com Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update Reported positive clinical proof-of-concept data for OD-001, our first-in-class, oral RIPK2 scaffolding inhibitor, in a Phase 2a monotherapy trial for moderate to severe ulcerative colitis Cash on…- benzinga.com Cantor Fitzgerald Initiates Coverage On Odyssey Therapeutics with Overweight Rating Cantor Fitzgerald analyst Eric Schmidt initiates coverage on Odyssey Therapeutics (NASDAQ:ODTX) with a Overweight rating.
- benzinga.com Wedbush Initiates Coverage On Odyssey Therapeutics with Outperform Rating, Announces Price Target of $30 Wedbush analyst David Nierengarten initiates coverage on Odyssey Therapeutics (NASDAQ:ODTX) with a Outperform rating and announces Price Target of $30.
benzinga.com JP Morgan Initiates Coverage On Odyssey Therapeutics with Overweight Rating, Announces Price Target of $26 JP Morgan analyst Brian Cheng initiates coverage on Odyssey Therapeutics (NASDAQ:ODTX) with a Overweight rating and announces Price Target of $26.
benzinga.com This Oppenheimer Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Wall Street analysts changed outlook on top names: ODTX, MOBI, MANE. See analyst ratings page for all changes. MOBI target prices: $16, $19, $31
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session 
benzinga.com Doximity, Aeluma, PDF Solutions And Other Big Stocks Moving Lower In Thursday's Pre-Market Session U.S. stock futures rise on Dow gaining 200 points. Doximity (DOCS) shares drop 21.3% after reporting mixed Q4 results and weak guidance. Other stocks also decline in pre-market trading.
gurufocus.com Healthcare IPOs Raise $4.7 Billion As Odyssey, Mobia Debuts Slip Healthcare IPO demand is coming back, but investors are not giving every new listing an easy first-day win. Odyssey Therapeutics (ODTX) and Mobia Medical (MOBI)
globenewswire.com Odyssey Therapeutics Announces Pricing of Upsized Initial Public Offering BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (“Odyssey”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from…
businesswire.com Odyssey Therapeutics Appoints Jolie M. Siegel as Executive Vice President, General Counsel BOSTON--(BUSINESS WIRE)--Odyssey Therapeutics announced the appointment of Jolie M. Siegel, Executive Vice President, General Counsel.
businesswire.com Odyssey Therapeutics Appoints Dennis Dean, Ph.D., as Executive Vice President, Head of Non-Clinical Development BOSTON--(BUSINESS WIRE)--Dennis Dean, Ph.D., appointed as Executive Vice President and Head of Non-Clinical Development at Odyssey Therapeutics.
businesswire.com Odyssey Therapeutics Appoints Pharmaceutical Leader Nia Tatsis, Ph.D., to Its Board of Directors BOSTON--(BUSINESS WIRE)--Odyssey announces appointment of Nia Tatsis, Ph.D., EVP of Vertex Pharmaceuticals, to its Board of Directors.
globenewswire.com Jeito Capital announces significant participation in oversubscribed $213M Series D financing for Odyssey Therapeutics to advance clinical pipeline addressing autoimmune diseases with high unmet needs Jeito Capital announces significant participation in oversubscribed $213M Series D financing for Odyssey Therapeutics to advance clinical pipeline addressing autoimmune diseases with high unmet needs